During MDUFA Negotiations, FDA Clarifies Plan of Action for LDT Oversight
July 20, 2011
During MDUFA Negotiations, FDA Clarifies Plan of Action for LDT Oversight
Agency officials said during a recent MDUFA meeting that there will be "three guidance documents coming out together that will detail the proposed road forward in oversight of laboratory-developed tests."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- CMS Issues Pricing for MDx Codes; Labs, Test Developers Still Critical of Rates and Methodology
May 22, 2013 / Pharmacogenomics Reporter - Industry-Backed Bill Introduced in House as Frustration Grows over CMS Payment Process for MDx
October 3, 2012 / Pharmacogenomics Reporter - Personalized Medicine Expert Spielberg Tapped for Center Coordination in FDA Restructuring
July 20, 2011 / Pharmacogenomics Reporter - FDA Draft Guidance on RUO/IUO Products Proposes Tough Changes for Industry Players
June 8, 2011 / Pharmacogenomics Reporter - At FDA Public Meeting on LDT Regulation, Dx Firms, Labs Suggest Areas for Agency Attention
July 28, 2010 / Pharmacogenomics Reporter